TRiP SystemTM



 

For lentiviral vectors, AAV and adenoviruses

The TRiP SystemTM maximises vector production yield and and improves  product quality.

Vector yields and quality can be dramatically reduced by expression of the transgene during vector production.  Additionally, the vector particle can be contaminated by the transgene protein. This makes purification more challenging, reduces product purity and raises immunogenicity concerns.

Our ’Transgene Repression in Vector Production’ (TRiP) SystemTM temporarily stops the production of the transgene protein during manufacture of vector particles.

The TRiP SystemTM can significantly improve yield and particle purity. It also enables the development of vectors carrying cytotoxic transgenes, or those that inhibit cell growth.

The TRiP SystemTM works by transfecting a plasmid encoding the bacterial tryptophan RNA-binding attenuation protein (TRAP) in production cells. A TRAP binding sequence (tbs) is inserted upstream of the transgene in the vector genome. In production cells, in excess of L-tryptophan, the TRAP protein binds to the tbs sequence and blocks translation of the transgene mRNA.

How TRiP works

 

 

The TRiP SystemTM enables production of toxic transgenes – returning titre to marker gene levels

 

Publications

Maunder et al. (2017) Nat Communications 8:14834

Farley (2018) Cell Gene Therapy Insights 2018; 4(10), 983-994

 

Intellectual Property: WO 2015/092440

 

Advantages:

Efficient:

  • Improves vector yield and particle quality
  • Enables development of viral vectors carrying cytotoxic transgenes
  • Standardises downstream processes

Broadly applicable:

  • Across key vector platforms including Lentiviral, AAV and Adenoviral based vector systems
  • Can be used in transient transfection and with stable producer cell lines

Multifunctional:

  • Transgene and promoter independent
  • Works with IRES elements and multicistronic cassettes